![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 43, 30349-30352, October 22, 1999
From the Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
| |
ABSTRACT |
|---|
|
|
|---|
A key step in the signaling mechanism of the
mitogen-activated protein kinase/extracellular signal-responsive kinase
(ERK) cascade is its translocation into the nucleus where it regulates transcription and other nuclear processes. In an attempt to
characterize the subcellular localization of ERK2, we fused it to the
3'-end of the gene expressing green fluorescent protein (GFP),
resulting in a GFP-ERK2 protein. The expression of this construct in
CHO cells resulted in a nuclear localization of the GFP-ERK2 protein. However, coexpression of the GFP-ERK2 with its upstream activator, MEK1, resulted in a cytosolic retention of the GFP-ERK2, which was the
result of its association with MEK1, and was reversed upon stimulation.
We then examined the role of the C-terminal region of ERK2 in its
subcellular localization. Substitution of residues 312-319 of GFP-ERK2
to alanine residues prevented the cytosolic retention of ERK2 as well
as its association with MEK1, without affecting its activity. Most
important for the cytosolic retention are three acidic amino acids at
positions 316, 319, and 320 of ERK2. Substitution of residues 321-327
to alanines impaired the nuclear translocation of ERK2 upon mitogenic
stimulation. Thus, we conclude that residues 312-320 of ERK2 are
responsible for its cytosolic retention, and residues 321-327 play a
role in the mechanism of ERK2 nuclear translocation.
Mitogen-activated protein kinase
(MAPK)1 signaling cascades
are main routes of communication between the plasma membrane and regulatory intracellular targets and thus initiate a large array of
cellular responses (1-4). The first MAPK cascade elucidated is the one
that signals through the extracellular signal-responsive kinases 1 and
2 (ERK1/2), which are activated via a sequential phosphorylation and
activation of the protein kinases Raf1 and MAPK/ERK kinase (MEK). Upon
activation, ERK phosphorylates and activates several regulatory
targets, which eventually culminate in regulation of proliferation,
differentiation, and other cellular processes.
Key steps in the signaling mechanism of the ERK cascade are the changes
in localization of its components upon stimulation. In resting cells,
all components of the cascade seem to be localized primarily in the
cell cytosol. However, this localization is rapidly changed upon
extracellular stimulation, which causes Raf1 recruitment to the plasma
membrane (5) and translocation of MEK (6), ERK (7), and RSK (7) into
the nucleus. After translocation, MEK seems to be rapidly exported from
the nucleus by its nuclear export signal (NES; Ref. 8), although the
timing and role of its translocation are still controversial (9, 10).
ERK and RSK on the other hand are retained in the nucleus for longer
times after stimulation, and this longer time is correlated with the effects of ERK on mitogenesis and neurite outgrowth in PC12 cells (11,
12).
The mechanism of nuclear translocation of the different kinases is not
fully understood. Recently, it was shown that in resting cells ERK is
retained in the cytosol by its association with MEK (10), and upon
stimulation ERK is detached from this cytosolic anchor to rapidly
translocate into the nucleus. This translocation requires dimerization
and phosphate incorporation into the regulatory Thr and Tyr residues of
at least one of the ERKs in the dimer (13). Here we further support the
cytosolic retention of mammalian ERK2 by MEK1, which is reversed upon
stimulation. We find that residues 312-320 of ERK2 play a
crucial role in its MEK-induced cytosolic retention, and thus prevent
nuclear localization of ERK in resting cells. We also provide evidence
that residues 321-327 play a role in the nuclear translocation of
ERK2. Thus, the 312-327 region of ERK2 plays an important role in
securing the proper subcellular localization of ERK2 both before and
after stimulation.
DNA Constructs--
Wild type ERK2 (bases 22-1096) was ligated
into ApaI and XbaI sites downstream to green
fluorescent protein (GFP) gene of pEGFP-C1 (CLONTECH). Mutations in
ERK2 (GFP-312A, GFP-316A, GFP-321A, GFP-328A, GFP- Transfection and Localization Studies--
The various plasmids
were transfected into CHO cells using LipofectAMINE (Life Technologies,
Inc.). Immunofluorescence studies were performed essentially as
described (6). Cells were stimulated with peroxyvanadate (VOOH; 100 µM Na3VO4/200 µM
H2O2, 15 min), fixed (3% paraformaldehyde),
and visualized by fluorescence microscopy (Zeiss Axioscop microscope,
HBO 100 W/2; ×400 magnification). For HA-ERKs, cells were stained with
anti-HA polyclonal antibody (1:100, Santa Cruz Biotechnology), and
rhodamine-conjugated goat-anti-rabbit antibodies (1:100, Jackson ImmunoResearch).
Western Blotting--
Transfected cells were serum-starved,
stimulated, and lysed as described previously (6). Activated ERK was
detected by probing blots with anti-activated ERK monoclonal antibody
(1:30,000, DP ERK, Sigma Israel). Total ERK protein was detected using
either anti-ERK2 C-terminal antibodies (C-14, Santa Cruz Biotechnology) or anti-MAPK (Sigma, Israel). MEK1 was detected with anti-MEK1 monoclonal (Transduction Laboratories).
Immunoprecipitation--
Transfected CHO cells were
serum-starved (24 h), stimulated (VOOH, 15 min), and harvested as
described (6). The cell extracts were then subjected to
immunoprecipitation with anti-GFP monoclonal antibody (Roche Molecular
Biochemicals). For MEK1 coimmunoprecipitation studies, the beads were
washed as described (10) with low stringency buffer (20 mM
HEPES, pH 8.0, 2 mM MgCl2 2 mM
EGTA) and then subjected to immunoblotting with monoclonal anti-MEK and
anti-GFP antibodies. For the determination of ERK activity, the beads
were washed once with 0.5 M LiCl, twice with radioimmune
precipitation buffer, and with buffer A (50 mM
In an attempt to characterize the subcellular localization of
ERK2, we fused the cDNA of rat ERK2 to the 3'-end of the gene expressing GFP, resulting in a GFP-ERK2 protein. This fused protein was
transfected into CHO cells and was examined for its subcellular localization using fluorescence microscopy. After serum
deprivation that ensures the cytosolic distribution of endogenous ERK1
and ERK2 (data not shown), GFP-ERK2 was localized primarily in the nucleus (Fig. 2). As reported for Xenopus MAPK (10), when
MEK was coexpressed with GFP-ERK2, the subcellular distribution of GFP-ERK2 was different and appeared primarily in the cytosol. After
stimulation with VOOH, a strong and non-selective activator of ERK, a
large portion of GFP-ERK2 was translocated into the nucleus. Nuclear
translocation was observed also with other stimuli (data not shown),
although, a small portion (<15%) of GFP-ERK2 was observed in the
cytosol under all conditions as described previously (15).
Because the C-terminal region of ERK2 plays an important role in the
localization and translocation of ERK2 (13, 16), we modified several
parts in this region (Fig. 1), which
include (i) deletion of the C terminus of ERK2 (amino acids 338-358,
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
COOH; see Fig. 1)
were performed by PCR mutagenesis as described (14). Wild type human
MEK1 (MKK1) was ligated into BamHI and EcoRV sites of pCDNA1
(Invitrogen) as described (6).
-glycerophosphate, pH 7.3, 1.5 mM EGTA, 1 mM
EDTA, 1 mM DTT, and 0.1 mM sodium vanadate) as
described (14). GFP-ERK2 activity was measured as described previously (14).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
COOH), (ii) substitution of amino acids 328-336 to alanines (328A),
(iii) substitution of amino acids 321-327 to alanines (321A), (iv)
substitution of amino acids 312-319 to alanines (312A), and (v)
substitution of Asp-316, Asp-319, and Glu-320 to alanines (316A). As
described for the GFP-ERK2, these constructs were fused to GFP and
expressed in CHO cells, either with or without exogenous MEK1. The
localization of
COOH and GFP-328A appeared similar to that of
GFP-ERK2 under all conditions and treatment used (data not shown). No
changes as compared with GFP-ERK2 were detected also when the other
three constructs 312A, 316A, and 321A, were expressed in CHO cells
without additional MEK1 (Fig. 2). On the
other hand, changes in localization were detected when these constructs
were coexpressed with exogenous MEK1. Thus, unlike GFP-ERK2, GFP-312A
was localized in the nucleus of resting cells, and this remained
unchanged after VOOH stimulation. Nuclear localization was observed
also with the GFP-316A protein, although the amount of this protein in
the cytosol of resting cells was higher than that of the GFP-312A
construct. GFP-321A had similar localization in resting cells as
GFP-ERK2 when coexpressed with MEK1. However, stimulation with VOOH
caused a uniform cellular distribution of this protein, indicating that
this mutated protein might be compromised in its ability to translocate
into the nucleus. To exclude the possibility that the altered
localization is because of the GFP part of the constructs, we
determined the localization of HA-ERK2 and HA-312A by staining with
anti-HA antibody. Indeed, both constructs demonstrated similar
distribution to that of their GFP counterparts (Fig. 2B,
left), indicating that the localization observed is indeed
because of ERK2. Interestingly, when the amount of transfected GFP-ERK2
was significantly reduced, the weak staining observed was either
cytosolic or spread all over the cell, even in the absence of exogenous
MEK1 (Fig. 2B, right). This cytosolic retention
can be explained by an interaction of GFP-ERK2 with residual,
unsaturated, cytosolic anchoring protein. Under these conditions,
GFP-312A was still detected in the nucleus, indicating that the
312-319 region is responsible for this interaction.
![]()
View larger version (9K):
[in a new window]
Fig. 1.
The sites of mutations and deletion made in
the C terminus of ERK2.

View larger version (80K):
[in a new window]
Fig. 2.
Localization of GFP-ERK2 and its mutants in
CHO cells. A, CHO cells were transfected with each of
the following constructs: GFP-ERK2, GFP-312A, GFP-316A, and GFP-321A,
either together with or without plasmid expressing MEK1. Cells were
serum starved and then were either left untreated (Basal) or
stimulated with VOOH, fixed, and visualized using conventional
fluorescence microscopy. B, left, CHO cells were
transfected with HA-ERK2 or HA-312A together with MEK1. Cells were
serum starved and stained with anti-HA antibodies. Right,
CHO cells were transfected with small amounts (*, 10 ng) of GFP-ERK2
and GFP-312A without MEK1. Each of these experiments was reproduced at
least three times.
The subcellular localization of the various GFP-ERK mutants was further
verified by isolating the nuclei of the GFP-ERK2 constructs-expressing CHO cells. As expected from the results in Fig. 2, Western blot analysis using anti-GFP antibodies revealed that the amount of GFP-ERK2
in the nucleus was reduced when coexpressed with MEK1 and elevated
again upon stimulation (Fig. 3). The
amount of GFP-312A and GFP-316A proteins in the nucleus was not
significantly changed when MEK1 was coexpressed, whereas the amount of
GFP-321A protein was reduced by MEK1 and only slightly enhanced after
VOOH-stimulation. Together, these results show that GFP-312A, and to a
lesser extent also GFP-316A, lost their MEK1-induced,
cytosolic-retention in resting cells. On the other hand, GFP-321A
protein exhibited a compromised VOOH-induced nuclear-translocation.
Hence, residues 312-327 play an important role in the subcellular
localization of ERK2 both before and after external stimulation.
|
To clarify whether these differences in subcellular localization are
because of altered ERK2 activation, we examined the phosphorylation state and catalytic activity of the various constructs. Thus, CHO cells
were transfected with GFP-ERK2, GFP-312A, GFP-316A, and GFP-321A,
either with or without MEK1. The cells were then lysed and
immunoblotted with either anti-general ERK or anti-diphospho ERK
antibodies. Beside the endogenous ERKs, an additional band of 70 kDa
was detected by the antibodies, which represents the GFP-ERKs. Similar
levels of expression of the various mutated proteins were detected by
the anti-general ERK antibodies (Fig. 4A). Interestingly, no
significant differences in the amount of phosphates incorporated into
the regulatory Thr and Tyr residues were detected between the various
mutants under any of the conditions used, indicating that the four GFP
proteins undergo proper upstream activation. We then examined whether
the various mutations affected the catalytic activity of ERK2. To do
so, the various GFP-conjugated ERKs were immunoprecipitated with
anti-GFP antibody and assayed for their ability to phosphorylate myelin
basic protein (MBP). The activity of the mutants did not differ from
that of GFP-ERK2, either with or without exogenous MEK1 (Fig.
4B). Therefore, these results indicate that residues
312-327 are not obligatory for either activation or catalytic activity
of ERK2, and exclude the possibility that the altered localization of
the modified proteins is because of compromised activation.
|
Because the cytosolic localization of GFP-ERK2 seems to be
MEK-dependent, we next asked whether this localization is
because of an association between ERK and MEK and whether the mutations in the C terminus interfere with this ERK-MEK association. Lysates from
CHO cells coexpressing MEK1 and the four GFP-ERK constructs were
subjected to immunoprecipitation with anti-GFP antibodies. As expected
(10), immunoblotting with anti-MEK1 antibodies showed coprecipitation
of MEK1 with GFP-ERK2, which was reversed upon VOOH stimulation (Fig.
5). However, this coimmunoprecipitation was not stable and was easily disrupted, even under mild washing conditions (e.g. 0.15 M NaCl; data not shown).
These results support the notion that, in resting cells, ERK and MEK
are indirectly associated and dissociate upon stimulation to allow
translocation of both MEK and ERK into the nucleus. On the other hand,
no coprecipitation of MEK was detected in immunoprecipitates of
GFP-312A either before or after stimulation. When GFP-316A was
immunoprecipitated from resting cells, a small amount of MEK1 was
coprecipitated, in agreement with the small amount of GFP-316A that
remained in the cytosol in the fluorescence studies (Fig. 2). As with
GFP-ERK2, VOOH reversed the coimmunoprecipitation of MEK by GFP-316A.
GFP-321A pulled down MEK1 from resting cells and less from
VOOH-stimulated cells, indicating that the association and dissociation
of this mutant from MEK1 were not affected. As expected, both GFP-ERK2
and GFP-312A did not interact with a constitutively active MEK1 (Fig.
5B), indicating that the activation of these cells by active
MEK was sufficient to prevent the ERK-MEK association.
|
| |
DISCUSSION |
|---|
|
|
|---|
The mechanism by which ERKs are retained in the cytosol of resting cells and translocated into the nucleus is not fully understood. Based on our and others studies (10, 16), it seems that ERK is kept out of the nucleus of resting cells by several anchoring proteins. One docking matrix is the microtubule cytoskeleton, which serves as a major docking matrix for up to 35% of the cellular ERK1 and ERK2 (15). Other putative anchoring proteins for ERK in the cytosol are MAP kinase phosphatases (MKPs) and in particular MKP3 (17, 18), but these interactions do not seem to be reversed by mitogenic stimulations.
Unlike the activity-independent binding of ERK to microtubules and MKPs, our results indicate that the cytosolic retention of ERK2 by MEK1 is reversed by mitogenic stimulation, thus allowing the nuclear translocation of ERK. Similar results were previously obtained for Xenopus ERK (10), and we noticed the same also with ERK1 (data not shown). However, the amount of endogenous MEK1 seems to be significantly lower than that of ERKs in many cells (20) and cannot account for the cytosolic retention of all ERKs. Moreover, ERK and MEK association is easily disrupted, and a small amount of ERK can be retained in the cytosol without exogenous MEK. It is therefore possible that additional proteins (e.g. the scaffold protein MP1 (21)) play a role in the reversible ERK retention in the cytosol, thus forming big signaling complexes, which may include more than one ERK molecule.
In this study we examined the role of the C-terminal region of ERK in determining its subcellular localization. We found that deletion of the C-terminal residues 338-358 or substitution of residues 328-336 to alanines did not affect the subcellular localization of ERK2. However, it was reported (13) that this combined C-terminal region (residues 328-358) contains a putative NES and dimerization-promoting leucine residues. A possible explanation for the lack of influence of the mutations is that each one of the mutations covers only part of the dimerization residues or the NES and the truncated parts are still active.
In contrast to residues 328-358, mutations in residues 321-327 affected nuclear translocation, and residues 312-320 affected cytosolic retention of ERK. The most important residues for the cytosolic retention seem to be the three acidic residues Asp-316, Asp-319, and Glu-320. However, because the effect of GFP-316A was weaker than that obtained with GFP-312A, it is likely that additional residues between 312-318 contribute to the cytosolic retention. Interestingly, Asp-319, which is substituted to Gln in the Drosophila sevenmaker gain-of-function mutant, was found to be responsible also for the binding of ERK to MKPs (18). However, because MKPs are inducible proteins (19) and are not expressed in any significant amount in resting CHO cells (data not shown), this association is unlikely to account for the cytosolic retention of ERK in resting cells.
Upon mitogenic stimulation, ERK (7) as well as MEK (6, 22) are activated and translocate into the nucleus. According to our results, this process involves dissociation of these two kinases. It is likely that after dissociation from the anchoring protein, ERK passively diffuses to the nuclear membrane and then penetrates to the nucleus by an unknown mechanism. The molecular size of the endogenous ERK and MEK (<50 kDa) may allow free diffusion into the nucleus. However, it was suggested that ERK undergoes a phosphorylation-dependent dimerization, which allows its proper translocation (13), and we show here that the 70-kDa GFP-ERK2 can rapidly translocate into the nucleus. Thus, it is likely that the molecular size of these proteins and the fast kinetic of translocation of the endogenous ERK requires an active mechanism, which might involve interactions with importins or exportins, to cross the nuclear membrane.
In summary, we found that substitution of residues 312-319 of ERK2
with alanine residues does not change its activity, but prevents
the cytosolic retention of ERK, as well as its association with MEK1.
Substitution of residues 321-327 to alanines impairs the nuclear
translocation of ERK2 upon mitogenic stimulation. We conclude that
residues 312-327 of ERK2 play a role in its subcellular localization
both before and after stimulation.
| |
FOOTNOTES |
|---|
* This work was supported by grants from MINERVA and from the Israel Cancer Research Fund.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 972-8-9343602;
Fax: 972-8-9344116; E-mail: bmseger@weizmann.weizmann.ac.il.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: MAPK, mitogen-activated protein kinase; DTT, dithiothreitol; ERK, external signal-responsive kinase; GFP, green fluorescent protein; HA, hemagglutinin; MBP, myelin basic protein; MEK, MAPK/ERK kinase; VOOH, peroxyvanadate; NES, nuclear export signal; PCR, polymerase chain reaction; CHO, Chinese hamster ovary; PAGE, polyacrylamide gel electrophoresis.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Seger, R., and Krebs, E. G. (1995) FASEB J. 9, 726-735[Abstract] |
| 2. | Lewis, T. S., Shapiro, P. S., and Ahn, N. G. (1998) Adv. Cancer Res. 74, 49-139[Medline] [Order article via Infotrieve] |
| 3. |
Widmann, C.,
Gibson, S.,
Jarpe, M. B.,
and Johnson, G. L.
(1999)
Physiol. Rev.
79,
143-180 |
| 4. | Cobb, M. (1999) Prog. Biophys. Mol. Biol. 71, 479-500[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Leevers, S. J., Paterson, H. F., and Marshall, C. J. (1994) Nature 369, 411-414[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Jaaro, H.,
Rubinfeld, H.,
Hanoch, T.,
and Seger, R.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3742-3747 |
| 7. |
Chen, R. H.,
Sarnecki, C.,
and Blenis, J.
(1992)
Mol. Cell. Biol.
12,
915-927 |
| 8. |
Fukuda, M.,
Gotoh, I.,
Gotoh, Y.,
and Nishida, E.
(1996)
J. Biol. Chem.
271,
20024-20028 |
| 9. |
Fukuda, M.,
Gotoh, I.,
Adachi, M.,
Gotoh, Y.,
and Nishida, E.
(1997)
J. Biol. Chem.
272,
32642-32648 |
| 10. | Fukuda, M., Gotoh, Y., and Nishida, E. (1997) EMBO J. 16, 1901-1908[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Traverse, S., Gomez, N., Paterson, H., Marshall, C., and Cohen, P. (1992) Biochem. J. 288, 351-355 |
| 12. |
Nguyen, T. T.,
Scimeca, J. C.,
Filloux, C.,
Peraldi, P.,
Carpentier, J. L.,
and Van-Obberghen, E.
(1993)
J. Biol. Chem.
268,
9803-9810 |
| 13. | Khokhlatchev, A. V., Canagarajah, B., Wilsbacher, J., Robinson, M., Atkinson, M., Goldsmith, E., and Cobb, M. H. (1998) Cell. 93, 605-615[CrossRef][Medline] [Order article via Infotrieve] |
| 14. |
Silverman, M. A.,
Benard, O.,
Jaaro, H.,
Rattner, A.,
Citri, Y.,
and Seger, R.
(1999)
J. Biol. Chem.
274,
2631-2636 |
| 15. |
Reszka, A. A.,
Seger, R.,
Diltz, C. D.,
Krebs, E. G.,
and Fischer, E. H.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
8881-8885 |
| 16. |
Lenormand, P.,
Sardet, C.,
Pages, G.,
L'Allemain, G.,
Brunet, A.,
and Pouyssegur, J.
(1993)
J. Cell Biol.
122,
1079-1088 |
| 17. | Brunet, A., Roux, D., Lenormand, P., Dowd, S., Keyse, S., and Pouyssigur, J. (1999) EMBO J. 18, 664-674[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Camps, M.,
Nichols, A.,
Gillieron, C.,
Antonsson, B.,
Muda, M.,
Chabert, C.,
Boschert, U.,
and Arkinstall, S.
(1998)
Science
280,
1262-1265 |
| 19. | Camps, M., Chabert, C., Muda, M., Boschert, U., Gillieron, C., and Arkinstall, S. (1998) FEBS Lett. 425, 271-276[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Ferrell, J. E., Jr. (1996) Trends Biochem. Sci. 21, 460-466[CrossRef][Medline] [Order article via Infotrieve] |
| 21. |
Schaeffer, H. J.,
Catling, A. D.,
Eblen, S. T.,
Collier, L. S.,
Krauss, A.,
and Weber, M. J.
(1998)
Science
281,
1668-1671 |
| 22. |
Tolwinski, N. S.,
Shapiro, P. S.,
Goueli, S.,
and Ahn, N. G.
(1999)
J. Biol. Chem.
274,
6168-6174 |
This article has been cited by other articles:
![]() |
D. Chuderland, G. Marmor, A. Shainskaya, and R. Seger Calcium-mediated Interactions Regulate the Subcellular Localization of Extracellular Signal-regulated Kinases J. Biol. Chem., April 25, 2008; 283(17): 11176 - 11188. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. Yazicioglu, D. L. Goad, A. Ranganathan, A. W. Whitehurst, E. J. Goldsmith, and M. H. Cobb Mutations in ERK2 Binding Sites Affect Nuclear Entry J. Biol. Chem., September 28, 2007; 282(39): 28759 - 28767. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Aguirre, L. I. Plotkin, A. R. Gortazar, M. M. Millan, C. A. O'Brien, S. C. Manolagas, and T. Bellido A Novel Ligand-independent Function of the Estrogen Receptor Is Essential for Osteocyte and Osteoblast Mechanotransduction J. Biol. Chem., August 31, 2007; 282(35): 25501 - 25508. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bendetz-Nezer and R. Seger Role of Non-phosphorylated Activation Loop Residues in Determining ERK2 Dephosphorylation, Activity, and Subcellular Localization J. Biol. Chem., August 24, 2007; 282(34): 25114 - 25122. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Nakamura and G. L. Johnson Noncanonical Function of MEKK2 and MEK5 PB1 Domains for Coordinated Extracellular Signal-Regulated Kinase 5 and c-Jun N-Terminal Kinase Signaling Mol. Cell. Biol., June 15, 2007; 27(12): 4566 - 4577. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Burgermeister, D. Chuderland, T. Hanoch, M. Meyer, M. Liscovitch, and R. Seger Interaction with MEK Causes Nuclear Export and Downregulation of Peroxisome Proliferator-Activated Receptor {gamma} Mol. Cell. Biol., February 1, 2007; 27(3): 803 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Costa, M. Marchi, F. Cardarelli, A. Roy, F. Beltram, L. Maffei, and G. M. Ratto Dynamic regulation of ERK2 nuclear translocation and mobility in living cells J. Cell Sci., December 1, 2006; 119(23): 4952 - 4963. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ranganathan, M. N. Yazicioglu, and M. H. Cobb The Nuclear Localization of ERK2 Occurs by Mechanisms Both Independent of and Dependent on Energy J. Biol. Chem., June 9, 2006; 281(23): 15645 - 15652. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Molina, S. Grewal, and L. Bardwell Characterization of an ERK-binding Domain in Microphthalmia-associated Transcription Factor and Differential Inhibition of ERK2-mediated Substrate Phosphorylation J. Biol. Chem., December 23, 2005; 280(51): 42051 - 42060. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Almeida, L. Han, T. Bellido, S. C. Manolagas, and S. Kousteni Wnt Proteins Prevent Apoptosis of Both Uncommitted Osteoblast Progenitors and Differentiated Osteoblasts by {beta}-Catenin-dependent and -independent Signaling Cascades Involving Src/ERK and Phosphatidylinositol 3-Kinase/AKT J. Biol. Chem., December 16, 2005; 280(50): 41342 - 41351. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Tarrega, P. Rios, R. Cejudo-Marin, C. Blanco-Aparicio, L. van den Berk, J. Schepens, W. Hendriks, L. Tabernero, and R. Pulido ERK2 Shows a Restrictive and Locally Selective Mechanism of Recognition by Its Tyrosine Phosphatase Inactivators Not Shared by Its Activator MEK1 J. Biol. Chem., November 11, 2005; 280(45): 37885 - 37894. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. I. Plotkin, I. Mathov, J. I. Aguirre, A. M. Parfitt, S. C. Manolagas, and T. Bellido Mechanical stimulation prevents osteocyte apoptosis: requirement of integrins, Src kinases, and ERKs Am J Physiol Cell Physiol, September 1, 2005; 289(3): C633 - C643. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. I. Plotkin, J. I. Aguirre, S. Kousteni, S. C. Manolagas, and T. Bellido Bisphosphonates and Estrogens Inhibit Osteocyte Apoptosis via Distinct Molecular Mechanisms Downstream of Extracellular Signal-regulated Kinase Activation J. Biol. Chem., February 25, 2005; 280(8): 7317 - 7325. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-R. Chen, L. I. Plotkin, J. I. Aguirre, L. Han, R. L. Jilka, S. Kousteni, T. Bellido, and S. C. Manolagas Transient Versus Sustained Phosphorylation and Nuclear Accumulation of ERKs Underlie Anti-Versus Pro-apoptotic Effects of Estrogens J. Biol. Chem., February 11, 2005; 280(6): 4632 - 4638. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Aebersold, Y. D. Shaul, Y. Yung, N. Yarom, Z. Yao, T. Hanoch, and R. Seger Extracellular Signal-Regulated Kinase 1c (ERK1c), a Novel 42-Kilodalton ERK, Demonstrates Unique Modes of Regulation, Localization, and Function Mol. Cell. Biol., November 15, 2004; 24(22): 10000 - 10015. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Barr, R. M. Hopkins, P. M. Watt, and M. A. Bogoyevitch Reverse Two-hybrid Screening Identifies Residues of JNK Required for Interaction with the Kinase Interaction Motif of JNK-interacting Protein-1 J. Biol. Chem., October 8, 2004; 279(41): 43178 - 43189. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chen, M. Rusnak, R. R. Luedtke, and A. Sidhu D1 Dopamine Receptor Mediates Dopamine-induced Cytotoxicity via the ERK Signal Cascade J. Biol. Chem., September 17, 2004; 279(38): 39317 - 39330. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. P. Roux and J. Blenis ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions Microbiol. Mol. Biol. Rev., June 1, 2004; 68(2): 320 - 344. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Raviv, E. Kalie, and R. Seger MEK5 and ERK5 are localized in the nuclei of resting as well as stimulated cells, while MEKK2 translocates from the cytosol to the nucleus upon stimulation J. Cell Sci., May 1, 2004; 117(9): 1773 - 1784. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. W. Whitehurst, F. L. Robinson, M. S. Moore, and M. H. Cobb The Death Effector Domain Protein PEA-15 Prevents Nuclear Entry of ERK2 by Inhibiting Required Interactions J. Biol. Chem., March 26, 2004; 279(13): 12840 - 12847. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Toledano-Katchalski, J. Kraut, T. Sines, S. Granot-Attas, G. Shohat, H. Gil-Henn, Y. Yung, and A. Elson Protein Tyrosine Phosphatase {varepsilon} Inhibits Signaling by Mitogen-Activated Protein Kinases Mol. Cancer Res., May 1, 2003; 1(7): 541 - 550. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Maiyar, M. L.L. Leong, and G. L. Firestone Importin-alpha Mediates the Regulated Nuclear Targeting of Serum- and Glucocorticoid-inducible Protein Kinase (Sgk) by Recognition of a Nuclear Localization Signal in the Kinase Central Domain Mol. Biol. Cell, March 1, 2003; 14(3): 1221 - 1239. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Shibayama, R. Shibata-Seita, K. Miura, Y. Kirino, and K. Takishima Identification of a C-terminal Region That Is Required for the Nuclear Translocation of ERK2 by Passive Diffusion J. Biol. Chem., September 27, 2002; 277(40): 37777 - 37782. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Eblen, J. K. Slack, M. J. Weber, and A. D. Catling Rac-PAK Signaling Stimulates Extracellular Signal-Regulated Kinase (ERK) Activation by Regulating Formation of MEK1-ERK Complexes Mol. Cell. Biol., September 1, 2002; 22(17): 6023 - 6033. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. W. Whitehurst, J. L. Wilsbacher, Y. You, K. Luby-Phelps, M. S. Moore, and M. H. Cobb ERK2 enters the nucleus by a carrier-independent mechanism PNAS, May 28, 2002; 99(11): 7496 - 7501. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. L. Robinson, A. W. Whitehurst, M. Raman, and M. H. Cobb Identification of Novel Point Mutations in ERK2 That Selectively Disrupt Binding to MEK1 J. Biol. Chem., April 19, 2002; 277(17): 14844 - 14852. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Robinson, B.-e Xu, S. Stippec, and M. H. Cobb Different Domains of the Mitogen-activated Protein Kinases ERK3 and ERK2 Direct Subcellular Localization and Upstream Specificity in Vivo J. Biol. Chem., February 8, 2002; 277(7): 5094 - 5100. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Emrick, A. N. Hoofnagle, A. S. Miller, L. F. T. Eyck, and N. G. Ahn Constitutive Activation of Extracellular Signal-regulated Kinase 2 by Synergistic Point Mutations J. Biol. Chem., November 30, 2001; 276(49): 46469 - 46479. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Matsubayashi, M. Fukuda, and E. Nishida Evidence for Existence of a Nuclear Pore Complex-mediated, Cytosol-independent Pathway of Nuclear Translocation of ERK MAP Kinase in Permeabilized Cells J. Biol. Chem., November 2, 2001; 276(45): 41755 - 41760. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Pearson, F. Robinson, T. Beers Gibson, B.-e Xu, M. Karandikar, K. Berman, and M. H. Cobb Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions Endocr. Rev., April 1, 2001; 22(2): 153 - 183. [Abstract] [Full Text] |
||||
![]() |
M Neumann, E Afonina, F Ceccherini-Silberstein, S Schlicht, V Erfle, G. Pavlakis, and R Brack-Werner Nucleocytoplasmic transport in human astrocytes: decreased nuclear uptake of the HIV Rev shuttle protein J. Cell Sci., January 5, 2001; 114(9): 1717 - 1729. [Abstract] [PDF] |
||||
![]() |
|